Compare Aurora Cannabis Inc (ACB) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

YMAG trades at $11.70, up 2.01% today, but technical indicators signal bearish momentum with resistance at $12. The ETF maintains weekly dividend distributions, though recent analysis highlights concerns about NAV decay from its synthetic covered call strategy on Magnificent Seven stocks. Mixed sentiment prevails with some analysts seeing tactical opportunities in rangebound markets while others cite limited upside potential.

Outlook remains cautious due to structural NAV erosion risks and high expense ratios. The fund's performance depends heavily on volatility monetization from its underlying option strategy, creating both income opportunities and capital depreciation risks in trending markets. Investors should weigh the high yield against potential long-term underperformance versus the broader market.